PRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Prenetics Global Ltd is not a strong buy for a beginner, long-term investor at this moment. While the company has shown significant revenue growth and improved financial metrics, the lack of immediate positive trading signals, neutral trading sentiment, and the absence of recent news or catalysts make it less compelling for immediate investment. Additionally, the technical indicators and options data suggest limited short-term upside potential.
The stock exhibits bullish moving averages (SMA_5 > SMA_20 > SMA_200) and a positive MACD histogram of 0.175, indicating a potential upward trend. However, RSI at 56.291 is neutral, and the stock is currently trading below the pivot level of 21.44. Key resistance levels are at 22.979 and 23.931, while support levels are at 19.901 and 18.949.
Analysts have given 'Buy' ratings with price targets of $29 and $36, citing the success of the IM8 nutrition brand, which has scaled to over $100M in revenue. The company has also streamlined its operations by divesting non-core assets, generating $150M in proceeds.
The stock has a 70% chance to decline by -1.81% in the next day and -3.56% in the next week. Additionally, there is no recent news or significant trading activity from hedge funds, insiders, or Congress. The company is still unprofitable with a net income of -$28.1M in Q4 2025.
In Q4 2025, Prenetics reported a revenue increase of 248.57% YoY to $36.56M and a gross margin improvement to 59.47%. However, the company remains unprofitable with a net income of -$28.1M, though this represents a 72.05% YoY improvement. EPS also improved to -1.75, up 36.72% YoY.
Analysts from Lake Street and Roth Capital have initiated coverage with 'Buy' ratings and price targets of $29 and $36, respectively. They highlight the growth potential of the IM8 brand and the company's strategic shift to a focused consumer health platform.
